REMODELING MMPIS - MATRIX METALLOPROTEINASE INHIBITORS WILL BE APPROVED AS DRUGS, PROBABLY THIS YEAR, BUT QUESTIONS REMAIN CONCERNING THEIRSPECIFICITY, BIOAVAILABILITY, AND POTENTIAL LONG-TERM TOXICITY